Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

Summary by Benzinga
Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to date Separately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix's discovery pipeline …

1 Articles

BenzingaBenzinga
Center

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to date Separately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix's discovery pipeline …

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Monday, January 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Eli Lilly icon

Eli Lilly

San Diego icon

San Diego

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal